EU approves Otsuka's long-acting HAE drug Dawnzera An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.

#hereditaryangioedema #Otsuka #Ionis #Dawnzera #regulatoryapproval #Rarediseases #pharmanews #HAEdrug #Dawnzera #antisenseoligonucleotidebasedplasmaprekallikreininhibitor #PKKinhibitor #plasmaprekallikreininhibitor #PKK #EMA #HAEpatients #clinicaltrials #RNAtargetedtherapy
zurl.co/Zw7sM